Press Release

Integra LifeSciences Announces the Acquisition of Satelec Medical

French Manufacturer of Dissectron(R) Ultrasonic Surgical Aspirator

PLAINSBORO, N.J. and BORDEAUX, France - May 3, 2001 -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) announced today that it has acquired Satelec Medical, a subsidiary of the Satelec-Pierre Rolland group, for $3.6 million in cash. Satelec Medical, based in France, manufactures and markets the Dissectron(R) ultrasonic surgical aspirator console and a broad line of related handpieces. The Dissectron(R) is the leading ultrasonic surgical system in France. The Dissectron(R) product has United States FDA 510(k) clearance for neurosurgical applications and CE Mark Certification in the European Union. Revenues of the acquired business were approximately $1.5 million in 2000. The transaction is not expected to be dilutive to earnings.

Stuart M. Essig, Integra's President and Chief Executive Officer, commented "This acquisition is a significant step in the expansion of our European operations, following our recent purchase of GMSmbH, the German manufacturer of the LICOX(R) Brain Tissue Oxygen Monitoring System. The acquisition of Satelec Medical provides our Integra NeuroSciences division with another leading device for the international market and an existing infrastructure through which Integra can sell certain of its other products directly into France. We expect to augment Satelec Medical's focused neurosurgical sales team with several additional neurospecialists in the coming months."

The Dissectron(R) system applies ultrasonic energy to precisely fragment and emulsify soft tissue, which is subsequently aspirated, while preserving major blood vessels, nerves and elastic fibers. The system has been used internationally in a variety of surgical applications, including neurosurgery.

Satelec-Pierre Rolland will continue to manufacture the Dissectron(R) until production is transferred to Integra's Andover, England Selector(R) Integra Ultrasonic Aspirator manufacturing facility. Satelec-Pierre Rolland will also provide certain administrative and logistics services to Integra in France for a period of time following the acquisition.

Through its Selector(R) Integra Ultrasonic Aspirator product line, Integra NeuroSciences has gained extensive experience in the development, manufacturing and marketing of ultrasonic surgical systems for use in neurosurgery. Integra expects to continue to offer Selector(R) and Dissectron(R) to its international customers.

Integra NeuroSciences, the neurosurgical products division of Integra, designs, manufactures and sells implants, devices and monitors used in neurosurgery, neurotrauma, and related critical care. Including its seven-person clinical development team, Integra NeuroSciences has a 60 person direct selling effort in the United States and the United Kingdom. Integra NeuroSciences also sells its products in approximately 80 countries worldwide through a network of international distributors.

Integra LifeSciences Holdings Corporation has its corporate headquarters in Plainsboro, New Jersey. Manufacturing and research facilities are located throughout the world. The Company has approximately 550 permanent employees. Please visit the Company's Website at (http://www.Integra-LS.com).

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements relating to the sale of the Dissectron and other products in new markets and the manufacturing of the Dissectron products. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to adopt new product technologies may affect their acceptance in new markets and the inability to transfer manufacturing operations may affect future product sales of the Dissectron system. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in the Business section of Integra's Annual Report on Form 10-K for the year ended December 31, 2000 and information contained in subsequent filings with the Securities and Exchange Commission could affect Integra's actual results. Integra disclaims any obligation to update any of the forward-looking statements contained herein to reflect future events or developments.

Source: Integra LifeSciences Holdings Corporation

Contacts:

John B. Henneman, III
Chief Administrative Officer
Integra LifeSciences Holdings Corporation
609-936-2481
jhenneman@integra-ls.com
www.integra-LS.com

John Bostjancic
Director of Finance
Integra LifeSciences Holdings Corporation
609-936-2239
jbostjancic@integra-ls.com